Search alternatives:
linear decrease » linear increase (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), b large (Expand Search)
a large » _ large (Expand Search)
Showing 41 - 60 results of 3,993 for search '(( a ((teer decrease) OR (linear decrease)) ) OR ((( i large decrease ) OR ( a large decrease ))))', query time: 0.68s Refine Results
  1. 41
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 42
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 43
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 44
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 45
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 46
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 47
    Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i><sub><i>k</i></sub>; a–c and d–f decreasing porosity for outward and inward protection model respectively; <i>k</i><sub><i>L</i></sub> is head loss coefficient for inward protection model.

    Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i><sub><i>k</i></sub>; a–c and d–f decreasing porosity for outward and inward protection... by Akshay Anand (118579)

    Published 2025
    Save to List
    Saved in:
  8. 48
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 49
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 50
    Bacterial abundance in L2 larvae collected from larval flasks inoculated with decreasing quantities of glycerol stock (bacteria source).

    Bacterial abundance in L2 larvae collected from larval flasks inoculated with decreasing quantities of glycerol stock (bacteria source). by Margaret V. Becker (21387776)

    Published 2025
    Save to List
    Saved in:
  11. 51
    Maps of median projected λ<sub><i>S</i></sub> (a) and <i>R</i><sub>0</sub> (b) across 1st-level sub-national administrative regions in selected African countries.

    Maps of median projected λ<sub><i>S</i></sub> (a) and <i>R</i><sub>0</sub> (b) across 1st-level sub-national administrative regions in selected African countries. by Keith Fraser (1868587)

    Published 2024
    Save to List
    Saved in:
  12. 52
    Predicted distance (km) needed to achieve a correlation coefficient of at least r =  0.50 using the median-based linear regression models.

    Predicted distance (km) needed to achieve a correlation coefficient of at least r =  0.50 using the median-based linear regression models. by Claire Stevens (11127729)

    Published 2025
    Save to List
    Saved in:
  13. 53
    Maps of median projected λ<sub><i>S</i></sub> (a) and <i>R</i><sub>0</sub> (b) across 1st-level sub-national administrative regions in selected South American countries.

    Maps of median projected λ<sub><i>S</i></sub> (a) and <i>R</i><sub>0</sub> (b) across 1st-level sub-national administrative regions in selected South American countries. by Keith Fraser (1868587)

    Published 2024
    Save to List
    Saved in:
  14. 54
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 55
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 56
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 57
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 58
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 59
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 60
    Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive health behaviors (dark blue lines) compared to those who did not (light blue lines).

    Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: